Tempus AI, Inc. Class A Common Stock

Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The company maintains one of the world's largest libraries of multimodal clinical and molecular data and provides an operating system to make that data accessible and useful. Tempus operates through two primary segments: Diagnostics, which offers molecular testing services including comprehensive genomic profiling, hereditary cancer testing, and molecular residual disease (MRD) testing primarily in oncology; and Data and Applications, which licenses de-identified clinical and molecular data to pharmaceutical and biotechnology companies and provides AI-enabled analytics, clinical trial matching, and foundation models for drug discovery and development. The company's platform integrates genomic sequencing, clinical data abstraction, AI algorithms, and digital pathology to deliver personalized treatment insights to physicians and accelerate therapeutic development. Tempus serves oncologists, health systems, and life sciences companies including major pharmaceutical firms such as AstraZeneca, BioNTech, Daiichi Sankyo, and Incyte. The company recently agreed to acquire Personalis to strengthen its MRD capabilities and holds FDA companion diagnostic approvals for both tumor-only and tumor-normal comprehensive genomic profiling assays. Updated Jul 30, 2026